More Surufatinib Cheer For Chi-Med As Second NET Trial Stopped Early
Multi-Modal Candidate Meets Endpoint In Pancreatic Setting
Chi-Med’s surufatinib has come up trumps in a second trial in neuroendocrine tumors, after the monitoring committee recommended an early halt following achievement of its PFS target in the pancreatic setting.
